Towards Healthcare
Europe Life Science Market to Drive USD 74.02 Bn by 2034

Europe Life Science Market Sees Growth via AI and Drug Discovery

Based on market forecasts, the Europe life science market, projected at USD 22.56 billion in 2024, is expected to reach USD 74.02 billion by 2034, growing at a CAGR of 12.62% over the forecast period. The growing public health concerns, significant scientific advancements, industrial competitiveness, and sustainability initiatives supported the robust R&D in the life sciences sector in Europe. Europe dominated the market in 2024, driven by increased investments, the development of bio-based products, and a strong biotechnology and pharmaceutical footprint.

  • Insight Code: 6282
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

FAQ's

The Europe life science market is valued at USD 25.16 billion in 2025 and is on track to reach USD 74.02 billion by 2034, witnessing a steady CAGR of 12.62% during the forecast span.

Germany is currently leading the Europe life science market share 25% due to mergers and acquisitions, and technological innovations in genomics, gene editing, cell and gene therapies, digital health solutions, etc.

Some key players include Agilent Technologies, Illumina, Inc., Qiagen N.V., Sartorius AG, and Thermo Fisher Scientific Inc.

Key trends include advanced therapies, personalized medicine, regulations, and digital and technological transformation.

EIB, HIIP, ERC, WHO, CEPI, UNOPS, EU CTR, ASMS.